AEGON ASSET MANAGEMENT UK Plc Has $31.51 Million Holdings in Insulet Co. (NASDAQ:PODD)

AEGON ASSET MANAGEMENT UK Plc lessened its position in Insulet Co. (NASDAQ:PODD - Free Report) by 18.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 135,549 shares of the medical instruments supplier's stock after selling 30,702 shares during the period. AEGON ASSET MANAGEMENT UK Plc owned approximately 0.19% of Insulet worth $31,510,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Blue Trust Inc. increased its holdings in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after acquiring an additional 58 shares during the period. International Assets Investment Management LLC bought a new position in Insulet in the 2nd quarter valued at about $32,000. UMB Bank n.a. grew its position in Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock valued at $37,000 after buying an additional 81 shares in the last quarter. CVA Family Office LLC grew its position in Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier's stock valued at $50,000 after buying an additional 145 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV grew its position in Insulet by 159.2% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 254 shares of the medical instruments supplier's stock valued at $51,000 after buying an additional 156 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PODD. Canaccord Genuity Group increased their target price on shares of Insulet from $236.00 to $269.00 and gave the company a "buy" rating in a research report on Wednesday, September 25th. Barclays increased their target price on shares of Insulet from $200.00 to $220.00 and gave the company an "equal weight" rating in a research report on Monday, August 12th. Raymond James raised their price objective on shares of Insulet from $213.00 to $260.00 and gave the company an "outperform" rating in a research report on Monday, October 14th. BTIG Research raised their price objective on shares of Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a research report on Friday. Finally, Sanford C. Bernstein started coverage on shares of Insulet in a research report on Wednesday. They set an "outperform" rating and a $300.00 price objective for the company. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $246.80.

Insulet Stock Up 9.4 %

Shares of PODD traded up $23.02 during trading hours on Friday, reaching $268.00. The company's stock had a trading volume of 1,582,981 shares, compared to its average volume of 782,076. The firm has a market cap of $18.79 billion, a price-to-earnings ratio of 48.73, a P/E/G ratio of 4.47 and a beta of 1.22. Insulet Co. has a 1-year low of $151.56 and a 1-year high of $275.52. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. The company has a 50 day moving average of $232.01 and a two-hundred day moving average of $203.96.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing analysts' consensus estimates of $0.56 by ($0.01). The business had revenue of $488.50 million during the quarter, compared to analyst estimates of $488.00 million. Insulet had a net margin of 21.11% and a return on equity of 30.73%. Insulet's revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.38 EPS. As a group, research analysts predict that Insulet Co. will post 3.04 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.